Skip to main content
. Author manuscript; available in PMC: 2009 Jun 28.
Published in final edited form as: Lung Cancer. 2007 Nov 19;60(2):259–263. doi: 10.1016/j.lungcan.2007.09.018

Table 3.

Most commonly observed toxicities

Toxicity Grade 3: No. pts (%) Grade 4: No. pts (%)
Hematological
Anemia 10 (20%) 2 (4%)
Leukopenia 14 (28%) 1 (2%)
Febrile neutropenia 1 (2%) 0 (0%)
Neutropenia 15 (30%) 10 (20%)
Red blood cell transfusion 15 (30%) 0 (0%)
Thrombocytopenia 16 (32%) 0 (0%)
Non-Hematological
ARDS 0 (0%) 1 (2%)
Constipation 2 (4%) 0 (0%)
Cough 3 (6%) 0 (0%)
Creatinine increase 0 (0%) 1 (2%)
Dehydration 2 (4%) 0 (0%)
Dyspnea 8 (16%) 2 (4%)
Fatigue/Malaise 11 (22%) 1 (2%)
Hypersensitivity reactions 1 (2%) 0 (0%)
Infections 3 (6%) 0 (0%)
Inner ear hearing loss 2 (4%) 0 (0%)
Motor neuropathy 1 (2%) 0 (0%)
Muscle weakness 3 (6%) 0 (0%)
Nausea 3 (6%) 0 (0%)
Sensory neuropathy 1 (2%) 0 (0%)
Somnolence 2 (4%) 0 (0%)